Assessment strategies and decision criteria for pesticides with endocrine disrupting properties relevant to humans

Reproductive Toxicology

Volumn 31, Issue 4, 2011, Pages 574-584

  Marx Stoelting, P ^a   Pfeil, R ^a   Solecki, R ^a   Ulbrich, B ^a   Grote, K ^a   Ritz, V ^a   Banasiak, U ^a   Heinrich Hirsch, B ^a   Moeller, T ^a   Chahoud, I ^b   Hirsch Ernst, K I ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Endocrine disruption; Plant protection product; Risk assessment

Indexed keywords

ENDOCRINE DISRUPTOR; PESTICIDE;

ADVERSE OUTCOME; CHEMICAL LABELING; CLINICAL DECISION MAKING; CONCENTRATION (PARAMETERS); CONCEPTUAL FRAMEWORK; CONFERENCE PAPER; DECISION TREE; EVALUATION RESEARCH; GOVERNMENT REGULATION; HEALTH HAZARD; HUMAN; NONHUMAN; POPULATION EXPOSURE; PRACTICE GUIDELINE; RISK ASSESSMENT;

ANIMALS; DATA MINING; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; ENDOCRINE DISRUPTORS; ENVIRONMENTAL MONITORING; EUROPE; GUIDELINES AS TOPIC; HUMANS; PESTICIDES; RISK ASSESSMENT; TOXICITY TESTS;

ANIMALIA;

EID: 79956359535     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2011.02.003     Document Type: Conference Paper

References (75)

1. Colborn T., vom Saal F.S., Soto A.M. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993, 101(October (5)):378-384.
2. Gore A.C. Developmental programming and endocrine disruptor effects on reproductive neuroendocrine systems. Front Neuroendocrinol 2008, 29(June (3)):358-374.
3. Sharpe R.M. Pathways of endocrine disruption during male sexual differentiation and masculinization. Best Pract Res Clin Endocrinol Metab 2006, 20(March (1)):91-110.
4. Zoeller R.T. Environmental chemicals impacting the thyroid: targets and consequences. Thyroid 2007, 17(September (9)):811-817.
5. Harvey P.W., Everett D.J. The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for human health?. J Appl Toxicol 2003, 23(March (2)):81-87.
6. Kortenkamp A. Ten years of mixing cocktails: a review of combination effects of endocrine-disrupting chemicals. Environ Health Perspect 2007, 115(December (Suppl. 1)):98-105.
7. Diamanti-Kandarakis E., Bourguignon J.P., Giudice L.C., Hauser R., Prins G.S., Soto A.M., et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009, 30(June (4)):293-342.
8. Shaw I. Endocrine-disrupting chemicals in food 2009, Woodhead Publishing Ltd., Cambridge. 1st ed.
9. Hotchkiss A.K., Rider C.V., Blystone C.R., Wilson V.S., Hartig P.C., Ankley G.T., et al. Fifteen years after "Wingspread" -environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go. Toxicol Sci 2008, 105(October (2)):235-259.
10. Anway M.D., Cupp A.S., Uzumcu M., Skinner M.K. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005, 308(June (5727)):1466-1469.
11. Colborn T. Neurodevelopment and endocrine disruption. Environ Health Perspect 2004, 112(June (9)):944-949.
12. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971, 284(April (15)):878-881.
13. Batzler WU, Giersiepen K, Hentschel S, Husmann G, Kaatsch P, Katalinic A, et al. Deutsches Krebsregister; 2008.
14. Schwartz G.F., Hughes K.S., Lynch H.T., Fabian C.J., Fentiman I.S., Robson M.E., et al. Proceedings of the international consensus conference on breast cancer risk, genetics & risk management, April, 2007. Cancer 2008, 113(November (10)):2627-2637.
15. Patel A.R., Klein E.A. Risk factors for prostate cancer. Nat Clin Pract Urol 2009, 6(February (2)):87-95.
16. Birnbaum L.S., Fenton S.E. Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 2003, 111(April (4)):389-394.
17. Soto A.M., Vandenberg L.N., Maffini M.V., Sonnenschein C. Does breast cancer start in the womb?. Basic Clin Pharmacol Toxicol 2008, 102(February (2)):125-133.
18. Davis D.L., Bradlow H.L., Wolff M., Woodruff T., Hoel D.G., Anton-Culver H. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Perspect 1993, 101(October (5)):372-377.
19. Prins G.S. Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 2008, 15(September (3)):649-656.
20. Carlsen E., Giwercman A., Keiding N., Skakkebaek N.E. Declining semen quality and increasing incidence of testicular cancer: is there a common cause?. Environ Health Perspect 1995, 103(October (Suppl 7)):137-139.
21. Skakkebaek N.E. Endocrine disrupters and testicular dysgenesis syndrome. Horm Res 2002, 57(Suppl 2):43.
22. Safe S. Endocrine disruptors and human health: is there a problem. Toxicology 2004, 205(December (1-2)):3-10.
23. Newbold R.R., Padilla-Banks E., Snyder R.J., Phillips T.M., Jefferson W.N. Developmental exposure to endocrine disruptors and the obesity epidemic. Reprod Toxicol 2007, 23(April (3)):290-296.
24. Newbold R.R., Padilla-Banks E., Jefferson W.N., Heindel J.J. Effects of endocrine disruptors on obesity. Int J Androl 2008, 31(April (2)):201-208.
25. Beronius A., Ruden C., Hanberg A., Hakansson H. Health risk assessment procedures for endocrine disrupting compounds within different regulatory frameworks in the European Union. Regul Toxicol Pharmacol 2009 June.
26. Harvey P.W., Everett D.J. Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health. Best Pract Res Clin Endocrinol Metab 2006, 20(March (1)):145-165.
27. Regulation (EC) 1107/2009, 1107/2009, European Council; 2009.
28. Regulation (EC) No. 1272/2008, 1272/2008, European Council; 2008.
29. Baker V.A. Endocrine disrupters-testing strategies to assess human hazard. Toxicol In Vitro 2001, 15(August (4-5)):413-419.
30. Clode S.A. Assessment of in vivo assays for endocrine disruption. Best Pract Res Clin Endocrinol Metab 2006, 20(March (1)):35-43.
31. Mantovani A. Risk assessment of endocrine disrupters: the role of toxicological studies. Ann N Y Acad Sci 2006, 1076(September):239-252.
32. OECD OECD conceptual framework 2002.
33. Gelbke H.P., Kayser M., Poole A. OECD test strategies and methods for endocrine disruptors. Toxicology 2004, 205(December (1-2)):17-25.
34. Gelbke H.P., Hofmann A., Owens J.W., Freyberger A. The enhancement of the subacute repeat dose toxicity test OECD TG 407 for the detection of endocrine active chemicals: comparison with toxicity tests of longer duration. Arch Toxicol 2007, 81(April (4)):227-250.
35. Owens W., Koeter H.B. The OECD program to validate the rat uterotrophic bioassay: an overview. Environ Health Perspect 2003, 111(September (12)):1527-1529.
36. Owens W., Gray L.E., Zeiger E., Walker M., Yamasaki K., Ashby J., et al. The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses: phase 2 dose-response studies. Environ Health Perspect 2007, 115(5):671-678.
37. Council Directive 91/414/EEC, European Council; 1991.
38. Kavlock R.J., Daston G.P., DeRosa C., Fenner-Crisp P., Gray L.E., Kaattari S., et al. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect 1996, 104(August (Suppl. 4)):715-740.
39. Weybridge. European Workshop on the impact of endocrine disrupters on human health and wildlife. Report No.: Report of Proceedings EUR 17549; 1996.
40. WHO/IPCS The International Programme on Chemical Safety (IPCS): global assessment of the state-of-the-science of endocrine disruptors 2002, World Health Organization, Geneva.
41. Lewis R.W., Billington R., Debryune E., Gamer A., Lang B., Carpanini F. Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol 2002, 30(January (1)):66-74.
42. Dorato M.A., Engelhardt J.A. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul Toxicol Pharmacol 2005, 42(August (3)):265-274.
43. WHO/IPCS IPCS risk assessment terminology 2004.
44. DG Joint Research Centre Guidance to Regulation (EC) No. 1272/2008 on classification labelling and packaging of substances and mixtures 2009 July.
45. OECD. Endocrine disruption: a guidance document for histologic evaluation of endocrine and reproductive tests. Paris; 2009 [Report No.: 106].
46. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., et al. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 2006, 36(November (10)):781-792.
47. Boobis A.R., Doe J.E., Heinrich-Hirsch B., Meek M.E., Munn S., Ruchirawat M., et al. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 2008, 38(2):87-96.
48. Guyton K.Z., Barone S., Brown R.C., Euling S.Y., Jinot J., Makris S. Mode of action frameworks: a critical analysis. J Toxicol Environ Health B Crit Rev 2008, 11(January (1)):16-31.
49. Meek M.E., Berry C., Boobis A.R., Cohen S.M., Hartley M., Munn S., et al. Re: Guyton, Kathryn Z., Barone, Stanley, Jr., Brown, Rebecca C., Euling, Susan Y., Jinot, Jennifer, Makris, Susan (2008). Mode of action frameworks: a critical analysis. Journal of Toxicology and Environmental Health, Part B, 11(1): 16-31. J Toxicol Environ Health B Crit Rev 2008 October, 11(8):681-683.
50. Directive 396/2005, European Council; 2005.
51. Barlow S., Schlatter J. Risk assessment of carcinogens in food. Toxicol Appl Pharmacol 2009 November.
52. Pratt I., Barlow S., Kleiner J., Larsen J.C. The influence of thresholds on the risk assessment of carcinogens in food. Mutat Res 2009, 678(August (2)):113-117.
53. Kroes R., Kleiner J., Renwick A. The threshold of toxicological concern concept in risk assessment. Toxicol Sci 2005, 86(August (2)):226-230.
54. Calabrese E.J. Getting the dose-response wrong: why hormesis became marginalized and the threshold model accepted. Arch Toxicol 2009, 83(March (3)):227-247.
55. Calabrese E.J. Androgens: biphasic dose responses. Crit Rev Toxicol 2001, 31(July (4-5)):517-522.
56. vom Saal F.S., Timms B.G., Montano M.M., Palanza P., Thayer K.A., Nagel S.C., et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 1997, 94(5):2056-2061.
57. Welshons W.V., Thayer K.A., Judy B.M., Taylor J.A., Curran E.M., vom Saal F.S. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ Health Perspect 2003, 111(June (8)):994-1006.
58. Ashby J. Problems associated with the recognition and confirmation of low-dose endocrine toxicities. Nonlinearity Biol Toxicol Med 2003, 1(October (4)):439-453.
59. Ashby J., Tinwell H., Odum J., Lefevre P. Natural variability and the influence of concurrent control values on the detection and interpretation of low-dose or weak endocrine toxicities. Environ Health Perspect 2004, 112(June (8)):847-853.
60. Naciff J.M., Daston G.P. Toxicogenomic approach to endocrine disrupters: identification of a transcript profile characteristic of chemicals with estrogenic activity. Toxicol Pathol 2004, 32(July (Suppl 2)):59-70.
61. Marx-Stoelting P., Chahoud I., Moeller T., Pfeil R., Solecki R., Ulbrich B., et al. Substances with endocrine disrupting properties under new EU plant protection product regulation-establishment of assessment and decision criteria. Toxicol Lett 2009 September, 189(Suppl. 1):S268.
62. OECD Hershberger bioassay in rats: a short-term screening assay for (anti)androgenic properties 2009, OECD, Paris.
63. OECD Uterotrophic bioassay in rodents: a short-term screening test for oestrogenic properties 2007 October, OECD, Paris.
64. OECD Stably transfected human estrogen receptor-a transcriptional activation assay for detection of estrogenic agonist-activity of chemicals 2009 September, OECD, Paris.
65. ECETOC. Guidance on Identifying Endocrine Disrupting Effects B; 2009 June [Report No.: 106].
66. Ersdal G., Aven T. Risk informed decision-making and its ethical basis. Reliab Eng Syst Saf 2008, 93(February (2)):197-205.
67. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31(January (1)):27-36.
68. Crews D., McLachlan J.A. Epigenetics evolution, endocrine disruption, health, and disease. Endocrinology 2006, 147(June (6 Suppl.)):S4-10.
69. Jansen M.S., Nagel S.C., Miranda P.J., Lobenhofer E.K., Afshari C.A., McDonnell D.P. Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. Proc Natl Acad Sci USA 2004, 101(May (18)):7199-7204.
70. Tabb M.M., Blumberg B. New modes of action for endocrine-disrupting chemicals. Mol Endocrinol 2006, 20(March (3)):475-482.
71. Boobis A.R., Ossendorp B.C., Banasiak U., Hamey P.Y., Sebestyen I., Moretto A. Cumulative risk assessment of pesticide residues in food. Toxicol Lett 2008, 180(August (2)):137-150.
72. EFSA Panel on Plant Protection Products and their Residues (PPR Panel) Scientific opinion on risk assessment for a selected group of pesticides from the triazole group to test possible methodologies to assess cumulative effects from exposure through food from these pesticides on human health. EFSA J 2009, 7(9):1167.
73. Rider C.V., Furr J., Wilson V.S., Gray L.E. A mixture of seven antiandrogens induces reproductive malformations in rats. Int J Androl 2008, 31(April (2)):249-262.
74. Rider C.V., Wilson V.S., Howdeshell K.L., Hotchkiss A.K., Furr J.R., Lambright C.R., et al. Cumulative effects of in utero administration of mixtures of "antiandrogens" on male rat reproductive development. Toxicol Pathol 2009, 37(1):100-113.
75. Christiansen S., Scholze M., Dalgaard M., Vinggaard A.M., Axelstad M., Kortenkamp A., et al. Synergistic disruption of external male sex organ development by a mixture of four antiandrogens. Environ Health Perspect 2009, 117(December (12)):1839-1846.